Loading...

TVTX TRAVERE THERAPEUTICS INC US FDA Inspections 8-K Filing

TRVR

TVTX

TRAVERE THERAPEUTICS INC

(TVTX)

2026 8-K

Financial Results Announced

FDA Review Extended

Financial Results Update

Financial Results Update

FDA Update on FILSPARI

Financial Statements

Regulatory Compliance

Financial Statements

Financial Statements

New Product Launches

Earnings Update

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Q3 Earnings Report

Merger of Equals

Financial Results

Financial Performance

Quantitative Data

Quantitative Data

Other Special Situation

Resignation of CFO

Merger of Equals

Positive Study Results for ...

Merger of Equals

Quantitative Data

Filing with Quantitative Data

Financial Update

Quantitative Data

Filing with Quantitative Data

Financial Performance

Public Offering

Quantitative Data

Financial Results

Other Special Situation

External Links:

Travere Therapeutics, Inc. reported that on January 13, 2026, the FDA extended the review timeline for its supplemental New Drug Application for FILSPARI for FSGS to April 13, 2026, due to a Major Amendment submitted by the company, which provides additional clinical benefit data.

AI Assistant

TRAVERE THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.